DOP67: First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn’s Disease – Results from the TISKids studyECCO'22Year: 2022
Authors: Vuijk, S.(1);Jongsma, M.(1);Hoeven, B.(1);Cozijnsen, M.(1);van Pieterson, M.(1);de Meij, T.(2);Norbruis, O.(3);Groeneweg, M.(4);Wolters, V.(5);van Wering, H.(6);Hummel, T.(7);Stapelbroek, J.(8);van der Feen, C.(9);van Rheenen, P.(10);van Wijk, M.(2);Teklenburg, S.(3);Poleij, M.(11);Escher, J.(1);de Ridder, L.(1);
(1)Erasmus Medical Center/Sophia Children’s Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands;(2)Emma Children's Hospital- Amsterdam UMC- VU University, Paediatric Gastroenterology, Amsterdam, The Netherlands;(3)Isala Hospital, Paediatric Gastroenterology, Zwolle, The Netherlands;(4)Maasstad Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands;(5)Utrecht Medical Center/ Wilhelmina Children’s Hospital, Paediatric Gastroenterology, Utrecht, The Netherlands;(6)Amphia Hospital, Paediatric Gastroenterology, Breda, The Netherlands;(7)Medical Spectrum Twente, Paediatric Gastroenterology, Enschede, The Netherlands;(8)Catharina Hospital, Paediatric Gastroenterology, Eindhoven, The Netherlands;(9)Jeroen Bosch Hospital, Paediatric Gastroenterology, ‘s Hertogenbosch, The Netherlands;(10)University of Groningen- University Medical Center Groningen, Paediatric Gastroenterology, Groningen, The Netherlands;(11)Erasmus University Rotterdam, Health Policy and Management, Rotterdam, The Netherlands;
DOP68: CD-TREAT diet induces remission and improves quality of life in an open label trial in children and adults with active Crohn’s DiseaseECCO'22Year: 2022
Authors: Svolos, V.(1);Hansen, R.(1);Russell, R.(1);Gaya, D.R.(1);John Paul, S.(1);Macdonald, J.(1);Nichols, B.(1);Papadopoulou, R.(1);Logan, M.(1);Mckirdy, S.(1);Gervais, R.(1);Ijaz, U.(1);Milling, S.(1);Shields, S.(1);Wilson, D.(1);Henderson, P.(1);Din, S.(1);Ho, G.T.(1);Gerasimidis, K.(1);
(1)Glasgow Royal Infirmary New Lister Building, Department of Human Nutrition- School of Medicine- College of Medical- Veterinary and Life Sciences, Glasgow, United Kingdom;
DOP69: Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHANECCO'22Year: 2022
Authors: Guz Mark, A.(1,2);Aloi, M.(3);Scarallo , L.(4);Bramuzzo, M.(5);Escher, J.C.(6);Alvisi, P.(7);Henderson, P.(8);Hojsak, I.(9);Lev-Tzion, R.(10);El-Matary, W.(11);Schwerd, T.(12);Weiss, B.(13);Sladek, M.(14);Strisciuglio, C.(15);Müller, K.(16);Olbjørn, C.(17);Tzivinikos, C.(18);Yerushalmy-Feler, A.(19);Christiaens, A.(20);Norsa, L.(21);Viola, I.(22);de Ridder, L.(6);Shouval, D.(23);Lega, S.(5);Lionetti, P.(24);Catassi, G.(25);Assa, A.(26);
(1)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;(2)Tel-Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Umberto I Hospital, Pediatric and Gastroenterology Unit- Sapienza University of Rome, Rome, Italy;(4)Meyer children’s Hospital, Gastroenterology and Nutrition Unit, Florence, Italy;(5)Institute for Maternal and Child Health - IRCCS @Burlo Garofolo@, Gastroenterology- Digestive Endoscopy and Nutrition Unit, Trieste, Italy;(6)Erasmus MC-Sophia Children’s Hospital, Department of Pediatric Gastroenterology, Rotterdam, The Netherlands;(7)Maggiore hospital, Pediatric Gastroenterology unit, Bologna, Italy;(8)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(9)Children’s Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia;(10)Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(11)Pediatric Gastroenterology, University of Manitoba, Winnipeg, Canada;(12)Dr von Hauner Children's Hospital- LMU Munich, Department of Pediatrics, Munich, Germany;(13)Edmond & Lily Safra Children's Hospital- Sheba Medical Center and Sackler Faculty of Medicine- Tel Aviv University, Pediatric Gastroenterology Unit, Tel Aviv, Israel;(14)Jagiellonian University Medical College, Department of Pediatrics- Gastroenterology and Nutrition, Krakow, Poland;(15)Department of Woman- Child and General and Specialistic Surgery, University of Campania Vanvitelli, Naples, Italy;(16)Heim Pal National Institute for Pediatrics, Institute for Translational Medicine- Faculty of Medicine- University of Pécs, Budapest, Hungary;(17)Akershus university hospital, Department of Pediatric and Adolescent Medicine, Lørenskog, Norway;(18)Al Jalila Children ‘s Hospital - Mohammed Bin Rashid University, Paediatric Gastroenterology Department, Dubai, United Arab Emirates;(19)@Dana-Dwek@ Children's Hospital- Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine- Tel Aviv University, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(20)University Hospital Brussels, Pediatric Gastroenterology and Nutrition, Brussels, Belgium;(21)ASST Papa Giovanni XXIII, Pediatric Hepatology- Gastroenterology and Transplantation, Bergamo, Italy;(22)University of Messina, Pediatric Gastroenterology and Cystic Fibrosis Unit- Department of Human Pathology in Adulthood and Childhood @G. Barresi, Messina, Italy;(23)Schneider Children's Medical Center of Israel- Sackler Faculty of Medicine- Tel-Aviv University, Institute of Gastroenterology- Nutrition and Liver Diseases-- Israel, Petach Tikva, Israel;(24)Meyer Children’s Hospital- University of Florence, Department NEUROFARBA- Gastroenterology and Nutrition Unit, Florence, Italy;(25)Sapienza University of Rome - Umberto I Hospital, Pediatric and Gastroenterology Unit, Rome, Italy;(26)Shaare Zedek Medical Center- The Hebrew University of Jerusalem, Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;
DOP70: Anti-TNF withdrawal according to a risk-stratified protocol does not reduce the risk of relapse in patients with Inflammatory Bowel Disease in endoscopic remission: A prospective studyECCO'22Year: 2022
Authors: Mahmoud, R.(1);Savelkoul, E.(2);Mares, W.(3);Goetgebuer, R.(4,5);Witteman, B.(3);de Koning, D.(6);Minderhoud, I.(7);van Tuyl, S.(8);van Boeckel, P.(9);Mahmmod, N.(9);Lutgens, M.(10);Horjus, C.(11);Römkens, T.(12);Akol-Simsek, D.(13);Jansen, J.(14);Hoentjen, F.(2,15);Jharap, B.(16);Oldenburg, B.(1);
(1)University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(3)Gelderse Vallei Hospital, Department of Gastroenterology and Hepatology, Ede, The Netherlands;(4)Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(5)Amsterdam University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Gelre Hospital, Department of Gastroenterology and Hepatology, Apeldoorn, The Netherlands;(7)Tergooi Medical Centre, Department of Gastroenterology and Hepatology, Hilversum, The Netherlands;(8)Diakonessenhuis, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(9)St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(10)Elisabeth-TweeSteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(11)Rijnstate Hospital, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;(12)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;(13)Medical Centre de Veluwe, Department of Gastroenterology and Hepatology, Apeldoorn, The Netherlands;(14)Onze Lieve Vrouwe Gasthuis OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(15)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;(16)Meander Medical Centre, Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands;AWARE study group Dutch Initiative on Crohn's and Colitis
DOP71: Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studiesECCO'22Year: 2022
Authors: Weinstein, C.L.(1);Meehan, A.G.(2);Lin, J.(3);Govoni, M.(4);Qureshi, Z.P.(5);
(1)Merck & Co.- Inc., Clinical Research, Kenilworth, United States;(2)Merck & Co.- Inc., Global Scientific & Medical Publications, Kenilworth, United States;(3)Merck & Co.- Inc., Biostatistics, Kenilworth, United States;(4)MSD Italy, Medical Affairs, Rome, Italy;(5)Merck & Co.- Inc., Outcomes Research, Kenilworth, United States;
DOP72: The association of anti-tumor necrosis factor and thiopurine therapy with the risk of lymphoma among Inflammatory Bowel Disease patients: A nation-wide study from the epi-IIRNECCO'22Year: 2022
Authors: WatermanM.D, M.(1);Lavi, I.(2);Harel, S.(3);Focht, G.(4);Loewenberg Weisband, J.(5);Greenfeld, S.(6);Kariv, R.(6);Ledderman, N.(7);Matz, E.(8);Keinan-Boker, L.(9);Eizenstein, S.(10);Dotan, I.(11);Turner, D.(4);Levi, Z.(12);
(1)Department of Gastroenterology- Rambam Health Care Campus, Rappaport Faculty of Medicine - The Technion- Israel Institute of Technology, Haifa, Israel;(2)Lady Davis Carmel Medical Center, Department of Community Medicine and Epidemiology, Haifa, Israel;(3)Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel;(4)Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition- Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel;(5)Clalit Research Institute- Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel;(6)Maccabi Health Services, The Sackler Faculty of Medicine- Tel Aviv University, Tel Aviv, Israel;(7)Meuhedet, Health Services, Tel Aviv, Israel;(8)Leumit, Health Services, Tel Aviv, Israel;(9)School of Public Health, University of Haifa, Haifa, Israel;(10)School of Public Health, The Sackler Faculty of Medicine- Tel Aviv University, Tel Aviv, Israel;(11)Division of Gastroenterology- Rabin Medical Center- Petah Tikva, Sackler Faculty of Medicine- Tel Aviv University, Tel Aviv, Israel;(12)Division of Gastroenterology- Rabin Medical Center- Petah Tikva, Sackler Faculty of Medicine - Tel Aviv University, Tel Aviv, Israel;
DOP73: A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative ColitisECCO'22Year: 2022
Authors: Peyrin-Biroulet, L.(1);Arkkila, P.(2);Armuzzi, A.(3);Atreya, R.(4);Danese, S.(5);Ferrante, M.(6);Guardiola, J.(7);Jahnsen, J.(8);Louis, E.(9);Lukáš, M.(10);Reinisch, W.(11);Roblin, X.(12);Smith, P.J.(13);Kwon, T.S.(14);Kim, J.Y.(14);Yoon, S.W.(15);Kim, D.H.(15);
(1)Centre Hospitalier Régional Universitaire de Nancy, Gastroenterology Department, Nancy, France;(2)Helsinki University and Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland;(3)Gemelli Hospital Catholic University, Department of Medical and Surgical Sciences, Rome, Italy;(4)University Hospital Erlangen- Friedrich-Alexander-University of Erlangen-Nürnberg, Department of Internal Medicine 1, Erlangen, Germany;(5)University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(6)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(7)Bellvitge University Hospital- Bellvitge Biomedical Research Institute-IDIBELL- University of Barcelona- L'Hospitalet de Llobregat, Digestive Diseases Department, Barcelona, Spain;(8)University of Oslo/Akershus University Hospital, Institute of Clinical Medicine/Department of Gastroenterology, Oslo, Norway;(9)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(10)ISCARE Clinical Centre, Gastroenterology Department, Prague, Czech Republic;(11)Medical University of Vienna, Division of Gastroenterology and Hepatology, Vienna, Austria;(12)University Hospital of Saint-Etienne, Department of Gastroenterology, Saint-Etienne, France;(13)Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Department of Gastroenterology, Liverpool, United Kingdom;(14)Celltrion Healthcare, Market Access, Incheon, Korea- Republic Of;(15)Celltrion Healthcare, Medical Affairs Department, Incheon, Korea- Republic Of;
DOP74: Comparative effectiveness of vedolizumab and ustekinumab in Crohn’s Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResourceECCO'22Year: 2022
Authors: Desoki, R.(1,2);Balendran, K.(1);Kapizioni, C.(1);Shawky, R.(1);Parkes, M.(1);Raine, T.(1);
(1)Cambridge University Hospital, Gastroenterology, Cambridge, United Kingdom;(2)Alexandria University, Genetics Department, Alexandria, Egypt;
DOP75: Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry studyECCO'22Year: 2022
Authors: Straatmijer , T.(1);Visschedijk , M.(2);de Vries , A.(3);Hoentjen , F.(21);van Bodegraven , A.A.(5);Bodelier , A.G.L.(6);de Boer , N.K.H.(7);Dijkstra , G.(2);Festen , E.A.M.(2);Horjus , C.(8);Jansen , J.M.(9);Jharap , B.(10);Mares , W.(11);Oldenburg , B.(12);Ponsioen , C.Y.(13);Romkens , T.E.H.(14);Srivastava , N.(15);van der Voorn , M.M.(16);West , R.L.(17);van der Woude , J.C.(3);Wolvers , M.D.J.(18);Pierik , M.(19);van der Meulen , A.E.(20);Duijvestein , M.(4);
(1)Initiative on Crohn and Colitis, Gastroenterology, Amsterdam / Leiden, The Netherlands;(2)University Medical Center Groningen, Gastroenterology, Groningen, The Netherlands;(3)Erasmus Medical Center, Gastroenterology, Rotterdam, The Netherlands;(4)Radboud University Medical Center, Gastroenterology, Nijmegen, The Netherlands;(5)Zuyderland, Gastroenterology, Geleen, The Netherlands;(6)Amphia Hospital, Gastroenterology, Breda, The Netherlands;(7)Amsterdam University Medical Centre- Vrije Universiteit Amsterdam, Gastroenterology, Amsterdam, The Netherlands;(8)Rijnstate Hospital, Gastroenterology, Arnhem, The Netherlands;(9)Onze Lieve Vrouwe Gasthuis, Gastroenterology, Amsterdam, The Netherlands;(10)Meander Medical Center, Gastroenterology, Amersfoort, The Netherlands;(11)Ziekenhuis Gelderse Vallei, Gastroenterology, Ede, The Netherlands;(12)University Medical Center Utrecht, Gastroenterology, Utrecht, The Netherlands;(13)Amsterdam University Medical Center- University of Amsterdam- Gastroenterology Endocrinology Metabolism AGEM Research Institute, Gastroenterology, Amsterdam, The Netherlands;(14)Jeroen Bosch Hospital, Gastroenterology, 's-Hertogenbosch, The Netherlands;(15)Haaglanden Medical Center, Gastroenterology, Den Haag, The Netherlands;(16)Haga Hospital, Gastroenterology, Den Haag, The Netherlands;(17)Franciscus Gasthuis & Vlietland, Gastroenterology, Rotterdam, The Netherlands;(18)Amsterdam University Medical Center, Epidemiology and Data Science, Amsterdam, The Netherlands;(19)Maastricht University Medical Center +, Gastroenterology, Maastricht, The Netherlands;(20)Leiden University Medical Center, Gastroenterology, Leiden, The Netherlands;(21)University of Alberta, Division of Gastroenterology, Edmonton, Canada;Dutch Initiative on Crohn and Colitis
DOP76: Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agentECCO'22Year: 2022
Authors: Buisson, A.(1);Nachury, M.(2);Fumery, M.(3);Guilmoteau, T.(1);Leclerc, E.(1);Altwegg, R.(4);Serrero, M.(5);Mathieu, N.(6);Treton, X.(7);Vuitton, L.(8);Pereira, B.(9);Amiot, A.(10);Bouguen, G.(11);
(1)University Hospital Estaing, Department of Gastroenterology- IBD Unit, Clermont-Ferrand, France;(2)CHRU Lille, IBD Unit, Lille, France;(3)CHU Amiens, IBD Unit, Amiens, France;(4)CHU Montpellier, IBD Unit, Montpellier, France;(5)AP-HM, IBD Unit, Marseille, France;(6)CHU Grenoble, IBD Unit, Grenoble, France;(7)AP-HP Beaujon Hospital, IBD Unit, Paris, France;(8)CHU Besançon, IBD Unit, Besançon, France;(9)University Hospital Estaing, DRCI- Biostatistics Unit, Clermont-Ferrand, France;(10)AP-HP Creteil Hospital, IBD Unit, Paris, France;(11)CHU Rennes, IBD Unit, Rennes, France;
DOP77: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD studyECCO'22Year: 2022
Authors: Di Giuseppe, R.(1);Plachta-Danielzik, S.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Atreya, R.(10);Teich, N.(11);Trentmann, L.(12);Ehehalt, R.(13);Franzenburg, S.(2);Hartmann, P.(4);Schreiber, S.(14);
(1)Kompetenznetz Darmerkrankungen, Statistics and Epidemiology, Kiel, Germany;(2)Kompetenznetz Darmerkrankungen, Studienabteilung, Kiel, Germany;(3)Interdisciplinary Crohn Colitis Centre, Crohn Colitis Centre, Minden, Germany;(4)Gastroenterology Practice, Gastroenterology, Minden, Germany;(5)Gastroenterology Practice, Gastroenterology, Saarbrücken, Germany;(6)Gastroenterology Practice, Gastroenterology, Iserlohn, Germany;(7)Gastroenterology Practice, Gastroenterology, Kassel, Germany;(8)Gastroenterology Practice, Gastroenterology, Münster, Germany;(9)University Hospital Augsburg, Department of Gastroenterology, Augsburg, Germany;(10)University Hospital Erlangen- University of Erlangen-Nürnberg Erlangen, Department of Medicine- Medical Clinic 1, Erlangen, Germany;(11)Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten, Gastroenterology, Leipzig, Germany;(12)Gastroenterology Practice, Gastroenterology, Bremen, Germany;(13)University Hospital Heidelberg, Department of Gastroenterology, Heidelberg, Germany;(14)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;
DOP78: Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)ECCO'22Year: 2022
Authors: García García, M.J.(1);Rivero, M.(1);Fernández-Clotet, A.(2);de Francisco, R.(3);Sicilia, B.(4);Mesonero, F.(5);de Castro, M.L.(6);Casanova, M.J.(7);Bertoletti, F.(8);García Alonso, F.J.(9);López García, A.(10);Julián, B.(11);Calvet, X.(12);Barreiro-de Acosta, M.(13);Jara, L.(14);Varela, P.(15);Nuñez, A.(16);Ricart, E.(2);Riestra, S.(3);Arias, L.(4);Rodríguez, M.(17);Arranz, L.(18);Pajares, R.(19);Mena, R.(20);Calafat, M.(21);Camo, P.(22);Jiménez, L.(23);Ponferrada, A.(24);Madrigal, R.E.(25);Llao, J.(26);Sesé, E.(27);Almela, P.(28);Codesido, L.(29);de la Maza, S.(30);Leal, C.(31);Sánchez, E.(5);Pineda Mariño, J.R.(6);Domènech, E.(21);Chaparro, M.(7);P. Gisbert, J.(7); GETECCU
(1)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology, Santander, Spain;(2)Hospital Clinic of Barcelona- CIBERehd, Gastroenterology, Barcelona, Spain;(3)Hospital Universitario Central de Asturias- Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology, Oviedo, Spain;(4)Hospital Universitario de Burgos, IBD Unit- Gastroenterology, Burgos, Spain;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(7)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology, Madrid, Spain;(8)Hospital de la Santa Creu I Sant Pau, Gastroenterology, Barcelona, Spain;(9)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(10)Hospital del Mar, Gastroenterology, Barcelona, Spain;(11)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(12)Consorci Corporació Sanitària Parc Taulí, Gastroenterology, Sabadell, Spain;(13)Hospital Universitario Clínico de Santiago, Gastroenterology, Santiago de Compostela, Spain;(14)Hospital Universitario Fundación de Alcorcón, Gastroenterology, Alcorcón, Spain;(15)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(16)Hospital Universitario de Salamanca, Gastroenterology, Salamanca, Spain;(17)Hospital General Universitario de Ciudad Real, Gastroenterology, Ciudad Real, Spain;(18)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Tenerife, Spain;(19)Hospital Universitario Infanta Sofía, Gastroenterology, Madrid, Spain;(20)Consorci Sanitari de Terrasa, Gastroenterology, Barcelona, Spain;(21)Hospital Universitari Germans Trias I Pujol, Gastroenterology, Barcelona, Spain;(22)Hospital General San Jorge, Gastroenterology, Huesca, Spain;(23)Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain;(24)Hospital Infanta Leonor, Gastroenterology, Madrid, Spain;(25)Hospital Clínico Universitario de Valladolid, Gastroenterology, Valladolid, Spain;(26)Althaia Xarxa Assistencial Universitària de Manresa, Gastroenterology, Manresa, Spain;(27)Hospital Universitario Arnau de Vilanova de Lleida, Gastroenterology, Lleida, Spain;(28)Hospital General Universitario de Castellón, Gastroenterology, Castellón, Spain;(29)Complexo Hospitalario Universitario de Ourense, Gastroenterology, Ourense, Spain;(30)Hospital Universitario de Basurto, Gastroenterology, Bilbao, Spain;(31)Consorci Hospitalari de Vic, Gastroenterology, Vic, Spain;
DOP79: Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortiumECCO'22Year: 2022
Authors: Sudhakar, P.(1);Salomon, B.(2);Verstockt, B.(1,3);Ungaro, R.(4);Aden, K.(5); D'Haens, G.(6);Komori, K.(7);Guay, H.(8);Silverberg, M.(9);Vermeire, S.(1,3);Halfvarson, J.(10); The COLLIBRI consortium
(1)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing- Translational Research Center for Gastrointestinal Disorders TARGID, Leuven, Belgium;(2)Örebro University, School of Medical Sciences- Faculty of Medicine and Health, Örebro, Sweden;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology- KU Leuven, Leuven, Belgium;(4)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York- NY, United States;(5)Christian-Albrechts-University and University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany;(6)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Arena Pharmaceuticals, Translational Medicine, San Diego- CA, United States;(8)AbbVie Inc., Immunology Precision Medicine, Worcester- MA, United States;(9)Mount Sinai Hospital, Inflammatory Bowel Disease Centre-, Toronto- ON, Canada;(10)Örebro University, Department of Gastroenterology- Faculty of Medicine and Health, Örebro, Sweden;
DOP80: Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in Ulcerative Colitis (UC) (Phase 2b Vibrato study)ECCO'22Year: 2022
Authors: Hassan-ZahraeePhD, M.(1);Ye, Z.(1);Xi, L.(1);Banerjee, A.(1);He, W.(1);Dushin, E.(1);Lee, J.(1);Altintas, E.(2);Romatowski, J.(3);Leszczyszyn, J.(4);Danese, S.(5);Sandborn, W.J.(6);Banfield, C.(1);Gale, J.(7);Peeva, E.(7);Vincent, M.(7);Hyde, C.(1);Longman, R.(8);Hung, K.E.(7);
(1)Pfizer Inc., Early Clinical Development, Cambridge, United States;(2)Mersin University, Gastroenterology and Nutrition, Mersin, Turkey;(3)Provincial Complex Hospital, Gastroenterology, Bialystok, Poland;(4)Melita Medical, Endoscopic Surgery, Wrocław, Poland;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele Milano Italy, Gastroenterology and Endoscopy, Milano, Italy;(6)University of California San Diego, Division of Gastroenterology, San Diego, United States;(7)Pfizer Inc., Inflammation & Immunology, Cambridge, United States;(8)Weill Cornell Medical College, Division of Gastroenterology and Hepatology, New York, United States;
DOP81: Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studiesECCO'22Year: 2022
Authors: Verstockt, B.(1);Al Mahi, N.(2);Pivorunas, V.(3);Smaoui, N.(2);Guay, H.(3);Kennedy, N.A.(4);Hanauer, S.B.(5);Ferrante, M.(1);Panés, J.(6);Vermeire, S.(1);
(1)University Hospital Leuven & KU Leuven, Gastroenterology, Leuven, Belgium;(2)AbbVie Inc., Immunology, North Chicago, United States;(3)AbbVie Bioresearch Centre, Immunology, Worcester, United States;(4)Royal Devon and Exeter NHS Foundation Trust, Gastrointestinal and Liver Service, Exeter, United Kingdom;(5)Northwestern University Feinberg School of Medicine, Department of Medicine, Evanston, United States;(6)IDIBAPS- CIBERehd, Hospital Clinic de Barcelona, Barcelona, Spain;
DOP82: Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumabECCO'22Year: 2022
Authors: Schreiber, S.W.(1);Cross, R.(2);Panaccione, R.(3);D'Haens, G.(4);Bossuyt, P.(5);Colombel, J.F.(6);Louis, E.(7);Dubinsky, M.(6);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Cheng, E.(8);Ferrante, M.(9);
(1)University Hospital Schleswig-Holstein, Department Internal Medicine I- Kiel University, Kiel, Germany;(2)University of Maryland School of Medicine, Department of Medicine, Baltimore, United States;(3)University of Calgary, Inflammatory Bowel Disease Unit, Calgary- Alberta, Canada;(4)Amsterdam University Medical Centers, Department of Inflammatory Bowel Diseases, Amsterdam, Netherlands Antilles;(5)Imelda General Hospital, Inflammatory Bowel Disease Clinic, Bonheiden, Belgium;(6)Icahn School of Medicine, Department of Gastroenterology, Mt. Sinai, United States;(7)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(8)AbbVie Inc., Department of Gastroenterology, North Chicago, United States;(9)University Hospitals Leuven, KU Leuven, Leuven, Belgium;
DOP83: Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesECCO'22Year: 2022
Authors: Atreya, R.(1);Feagan, B.(2);Shchukina, O.(3);Jairath, V.(4);Rieder, F.(5);Hisamatsu, T.(6);Siegmund, B.(7);Rizzo, J.(8);Kligys, K.(8);Neimark, E.(8);Song, A.(8);Zambrano, J.(8);Mallick, M.(8);Cheng, E.(8);Armuzzi, A.(9);
(1)Friedrich-Alexander-University Erlangen-Nürnberg, Medicine, Erlangen, Germany;(2)Western University, Gastroenterology, London, Canada;(3)Pavlov First Saint Petersburg State Medical University, Gastroenterology, Saint Petersburg, Russian Federation;(4)Western University, Medicine, London, Canada;(5)Digestive Diseases and Surgery Institute- Cleveland Clinic, Gastroenterology- Hepatology and Nutrition, Cleveland, United States;(6)Kyorin University School of Medicine, Gastroenterology, Mitaka, Japan;(7)Charité – Universitätsmedizin Berlin, Department of Medicine Divisions of Gastroenterology- Infectious Diseases- Rheumatology, Berlin, Germany;(8)AbbVie Inc., Gastroenterology, North Chicago, United States;(9)Fondazione Policlinico Universitario A. Gemelli IRCCS, Gastroenterology, Rome, Italy;
DOP84: Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFYECCO'22Year: 2022
Authors: Irving, P.M.(1);Abreu, M.(2);Axler, J.(3);Gao, X.(4);Torres, J.(5);Neimark, E.(6);Song, A.(7);Wallace, K.(7);Kligys, K.(8);Berg, S.(8);Liao, X.(7);Panaccione, R.(9);
(1)St. Thomas' Hospital, Department of Gastroenterology, London, United Kingdom;(2)University of Miami Miller School of Medicine, Crohn's & Colitis Center, Miami, United States;(3)TDDA, Toronto Digestive Disease Associates Inc, Vaughan, Canada;(4)The Sixth Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology- The Center for Inflammatory Bowel Disease, Guangzhou-, China;(5)Hospital Beatriz Ângelo, Division of Gastroenterology-, Loures, Portugal;(6)AbbVie, Clinical Development, Worcester, United States;(7)AbbVie, Clinical Development, North Chicago, United States;(8)AbbVie, Global Medical Affairs, Mettawa, United States;(9)Cumming School of Medicine- University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada;
DOP85: Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapyECCO'22Year: 2022
Authors: Baert, F.J.(1);Atreya, R.(2);Kakuta, Y.(3);Long, M.(4);Roblin, X.(5);Neimark, E.(6);Song, A.(6);Wallace, K.(6);Kingys, K.(6);Mallick, M.(6);Liao, X.(6);Lim, A.(7);
(1)AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium;(2)Friedrich-Alexander-University Erlangen-Nürnberg- University Hospital Erlangen, Department of Medicine, Erlangen, Germany;(3)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Seiryo- Aoba- Sendai, Japan;(4)University of North Carolina, Division of Gastroenterology and Hepatology- Multidisciplinary Center for Inflammatory Bowel Diseases, Chapel Hill, United States;(5)University Hospital of Saint-Étienne, Department of Gastroenterology, Saint-Étienne, France;(6)AbbVie Inc., Department of Gastroenterology, North Chicago, United States;(7)John Flynn Private Hospital, Department of Gastroenterology, Tugun- Queensland, Australia;
DOP86: Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative ColitisECCO'22Year: 2022
Authors: Steere, B.(1);Powell, N.(2);Higgs, R.(1);Wang, Y.C.(1);Milch, C.(1);Sandborn, W.J.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Krishnan, G.(1);
(1)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(2)Imperial College London, Gastroenterology, London, United Kingdom;(3)University of California San Diego, Gastroenterology, San Diego, United States;(4)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(5)Medical University of Vienna, Internal Medicine, Vienna, Austria;(6)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;